Top 20 Global Pharmaceutical Companies Unveil IPO Prospectus Highlighting Comprehensive Cell and Gene Therapy Portfolios

According to the revenue of global pharmaceutical companies last year, the industry media Fierce Pharma previously announced the ranking of the top 20 global pharmaceutical companies. In this list, Pfizer, Johnson & Johnson, and Roche ranked in the top three.

WuXi AppTec Content Team (In this ranking, revenues from outside the health sciences field for each company are excluded, and dollar conversions are based on the annual average exchange rate.)

The world's top 20 pharmaceutical companies mentioned above have all laid out plans in cell and gene therapy (CGT):

Pfizer

Revenue in 2022:$100.3 billion

Revenue in 2021:$81.3 billion

Headquarters:New York City

Recommended reading article link:

1) $300 Million! Pfizer Introduces a Novel AAV Capsid for the Nervous System, Licensing Party's Stock Price Surges 17%

2) New Pioneer Developing Macrophage Therapy Secures $70 Million Investment from Pfizer

3) Pfizer Resumes Phase 3 Clinical Trial of DMD Gene Therapy, Solid Bio Updates Clinical Research Plan for DMD Gene Therapy

4) Over $600 Million Boosts Development of Novel AAV Gene Therapy, Pfizer Reaches Collaboration

Johnson & Johnson

Revenue in 2022:$94.9 billion

Revenue in 2021:$93.8 billion

Headquarters:New Brunswick, New Jersey

Recommended reading article link:

1) Johnson & Johnson/Legend Biotech suspends the launch of CAR-T cell therapy in the UK

2) Ophthalmology Gene Therapy! Johnson & Johnson's AAV-RPGR for Treating X-linked Retinitis Pigmentosa (XLRP): Significant Vision Improvement!

Roche

Revenue in 2022:$66.3 billion

Revenue in 2021:$68.7 billion

Headquarters:Basel, Switzerland

Recommended reading article link:

Over $6 billion! Roche enters the universal CAR-T therapy field

Over $1 billion! Roche partners with Avista to develop next-generation AAV gene therapy vectors for ocular diseases

3) The world's first DMD gene therapy is nearing market release as the FDA accepts Roche and Sarepta's BLA application for their DMD gene therapy.

Merck & Co., Inc. (MSD)

Revenue in 2022:$59.3 billion

Revenue in 2021:$48.7 billion

Headquarters:Kenilworth, New Jersey

Recommended reading article link:

1) Merck & Co. Acquires Viralytics for $396 Million, Expanding Oncolytic Virus Product Line

2) Merck Invests Over $3.5 Billion in Circular RNA

AbbVie

Revenue in 2022:$58.1 billion

Revenue in 2021:$56.2 billion

Headquarters:North Chicago, Illinois

Recommended reading article link:

1) Gene Therapy for Alzheimer's Disease: AbbVie Collaborates with Voyager Therapeutics on Research and Development

Over $660 Million! AbbVie Partners with Capsida on Gene Therapy for Eye Diseases

Novartis

Revenue in 2022:$50.5 billion

Revenue in 2021:$51.6 billion

Headquarters:Basel, Switzerland

Recommended reading article link:

1) Novartis Releases New Data: AAV Gene Therapy Zolgensma Shows Effectiveness for Up to 7.5 Years

2) Novartis announces new development strategy, prioritizing cell and gene therapies, radioligand therapy, and xRNA in biologics and technology platforms.

3) Novartis Completes $1.5 Billion Acquisition of Ophthalmology Gene Therapy Company Gyroscope Therapeutics

4) Novartis Acquires Another Gene Therapy Startup, Arctos Medical, Showing Confidence in Optogenetics Technology

5) Two shots a year for strong lipid reduction, Novartis' first-in-class small interfering RNA therapy Leqvio® receives FDA approval

Bristol Myers Squibb

Revenue in 2022:$46.2 billion

Revenue in 2021:$46.4 billion

Headquarters:New York City

Recommended reading article link:

1) Gilead, AZ, BMS Lay Out New Directions in Cell Therapy

2) $4 Billion | Evotec and BMS Deepen iPSC Collaboration to Advance in Neurodegenerative Diseases

3) BMS's CD19 CAR-T Approved for Marketing in the EU

Sanofi

Revenue in 2022:$45.2 billion

Revenue in 2021:$44.6 billion

Headquarters:Paris, France

Recommended reading article link:

1) 1.375 Billion Euros! Sanofi Boosts Investment in NK Cell Therapy Field

$400 Million! Sanofi Collaborates with RNA Therapy Start-up to Develop Antibody-RNA Conjugate Drugs

3) $1 Billion: Sanofi Collaborates with Scribe to Develop CAR-NK Therapy Using Gene Editing Technology

4) $3.2 Billion! Sanofi Acquires mRNA Company Translate Bio

AstraZeneca

Revenue in 2022:$44.4 billion

Revenue in 2021:$37.4 billion

Headquarters:Cambridge, UK

Recommended reading article link:

1) AstraZeneca’s $320 Million Acquisition of Neogene, Betting on T-Cell Therapy

2) Soaring 638%! AstraZeneca Acquires Gene Therapy Company LogicBio

3) AstraZeneca Acquires Novel T-Cell Immunotherapy for Over $1.2 Billion

GSK

Revenue in 2022:$36.2 billion

Revenue in 2021:$469 billion

Headquarters:Cambridge, UK

Recommended reading article link:

1) GSK and Novartis Acquire Bluebird Lentivirus Patent for Gene Therapy and CAR-T Cell Therapy Development

2) Why is GSK giving up at a critical moment?

Takeda

Revenue in 2022:$30 billion

Revenue in 2021:$31.6 billion

Headquarters:Tokyo, Japan

Recommended reading article link:

1) Takeda Collaboration: Non-Viral Gene Therapy Poised to Enter Clinical Trials

2) Takeda Pipeline Adjustment: Returns Gene Therapy Products Worth Over $1 Billion

Eli Lilly

Revenue in 2022:$28.6 billion

Revenue in 2021:$28.3 billion

Headquarters:Indianapolis, Indiana

Recommended reading article link:

1) $740 Million: Lilly and Capsida Reach Strategic Collaboration on AAV Gene Therapy Project

2) $610 Million! Eli Lilly Acquires Gene Therapy Company Akouos

3) On the basis of a $1 billion acquisition of gene therapy company Prevail Therapeutics, Eli Lilly and Company will invest $700 million to establish the Boston Gene Therapy Research Center.

Gilead Sciences

Revenue in 2022:$27.3 billion

Revenue in 2021:$27.3 billion

Headquarters:Foster City, California

Recommended reading article link:

1) Summary of 45 gene therapy drugs already on the market worldwide

2) CEO of Gilead's Kite Pharma to Step Down

Bayer

Revenue in 2022:$26.6 billion

Revenue in 2021:$27.9 billion

Headquarters:Leverkusen, Germany

Recommended reading article link:

1) Metagenomi, a gene editing technology company, raises nearly $300 million in Series B funding from Moderna, Bayer, and others, accelerating the development of gene editing products

2) A subsidiary of Bayer has been approved to conduct clinical trials for Huntington's gene therapy

3) Bayer Advances Two First-of-Their-Kind Cell and Gene Therapies for Parkinson's Disease

Amgen

Revenue in 2022:$26.3 billion

Revenue in 2021:$26 billion

Headquarters:Thousand Oaks, California

Recommended reading article link:

1) Amgen Partners with Advaxis to Develop Novel Cancer Immunotherapy Gene Therapy ADXS-NEO

2) Amgen's siRNA New Drug Initiates Clinical Trials in China, Reducing Cardiovascular Event Risk

Boehringer Ingelheim

Revenue in 2022:$25.3 billion

Revenue in 2021:$24.2 billion

Headquarters:Ingelheim am Rhein, Germany

Recommended reading article link:

1) Boehringer Ingelheim collaborates with top institutions to develop the first gene therapy for cystic fibrosis

2) Boehringer Ingelheim Acquires Oncolytic Virus Gene Therapy Company for $245 Million

Novo Nordisk

Revenue in 2022:$25 billion

Revenue in 2021:$22.4 billion

Headquarters:Bagsvaerd, Denmark

Recommended reading article link:

1）Entering Cell Therapy! Novo Nordisk's Cell Treatment Drug HS-001 Administered to First Patient

2）Gene Therapy Company Freeline Completes $120 Million Financing, Novo Nordisk Ventures Joins

Moderna

Revenue in 2022:$19.3 billion

Revenue in 2021:$18.5 billion

Headquarters:Cambridge, Massachusetts

Recommended reading article link:

1) Moderna Plans to Collaborate with Life Edit to Develop Gene Editing Therapies for Genetic Diseases

2) Is Moderna's mRNA Cancer Vaccine Close? Significant Reduction in Recurrence Rate of Advanced Skin Cancer!

3) Nearly $600 Million: Moderna Completes Its First Acquisition! Acquires OriCiro Genomics, a Pioneer in Cell-Free DNA Synthesis and Amplification Technology in Japan

4) mRNA drug company Moderna's stock price soars, market value surpasses century-old pharmaceutical giant Merck

Merck KGaA

Revenue in 2022:$19.2 billion

Revenue in 2021:$19.1 billion

Headquarters:Darmstadt, Germany

Recommended reading article link:

1) Merck Enhances Commercial Viral Vector and Gene Therapy Product Manufacturing Capabilities

2) Merck Develops Alternative CRISPR Genome Editing Method

BioNTech

Revenue in 2022:$18.2 billion

Revenue in 2021:$22.4 billion

Headquarters:Mainz, Germany

Recommended reading article link:

1) BioNTech Collaborates with Medigene to Develop TCR Cancer Immunotherapy

2) BioNTech Initiates Clinical Trials for mRNA Malaria Vaccine

Source: Official Account "Cell and Gene Therapy Field", WuXi AppTec

Previous article recommendations:

Beijing Adds Another Biomedical Industrial Park, Focusing on R&D and Production of Gene Drugs, Cell Drugs, etc.

Better than LNP? A Novel Dual-Targeting Extracellular Vesicle Delivery Platform for In Vivo Treatment of Solid Tumors

Another Global Headquarters Completed in Suzhou Industrial Park, with a Total Construction Area of 25,000 Square Meters

Lingtek Bio Completes Pre-A Round Financing of RMB 100 Million

First FDA-Approved Clinical Trial for In Vivo Base Editing Therapy

Shanghai ENT Hospital Establishes "Gene and Cell Therapy Center"

China's First CAR-Macrophage Therapy Product, CellOrigin SY001 Injection, Completes First Patient Dosing

Yisheng Biotech Completes Tens of Millions of Yuan in Financing

Shandong Issues New Policy, Encouraging Foreign Enterprises to Legally Conduct Clinical Trials in Shandong for Cell and Gene Therapy Drugs Already Marketed Overseas

Dinayuan Sheng Completes Pre-A+ Round Financing with Exclusive Investment from Panlin Capital

New Bio Completes $50 Million Pre-B Round Financing

Reaching 100 Billion by 2025! China Accelerates Cell Therapy Development

Total investment of 120 million yuan, building area of 14,000 square meters, another commercial production base project for cell therapy products in the Beijing-Tianjin-Hebei region has commenced.

Analysis of the Immunogenicity of mRNA Vaccines

Nine Skies Biotech's AAV Ophthalmology Gene Therapy Drug Approved by National Medical Products Administration for Clinical Trials

China’s First In Vivo Gene-Editing Drug Based on Non-Viral Vectors Enters IIT Human Clinical Trials, Showing Safety and Efficacy Potential

Feng Zhang's Team CRISPR Gene Editing Technology Platform Patent Partially Invalidated in China, Note that it is Partially Invalid!

Zuckerberg Invests $250 Million into the Cell Industry, with a Vision Far Beyond Current Medical Standards!

First Case in China! Xijing Hospital Successfully Treats Severe Burn Patient with Multi-Gene Edited Pig Skin

FDA Allows In Vivo Gene Editing Therapy Product to Proceed to Phase III Clinical Trial

Novartis' siRNA Long-Acting Lipid-Lowering Drug Inclisran Launched in China, One Injection at 9,988 Yuan

World's First! Professor Wang Gang's Team from Ruijin Hospital Completes Clinical Trial on Exosome Nasal Spray for Alzheimer's Disease Treatment

50 Gene Therapies Have Been Launched Globally, Gene Treatment to Enter a Period of Rapid Development

Priced at 1.166 million yuan per dose, the first China-produced self-developed CAR-T product commercializes with impressive clinical data

Central China's First Stem Cell Bank Established at Tongji Hospital

History of Clinical Development in Gene Therapy

CDE Releases "Technical Guiding Principles for Non-Clinical Research of Human Stem Cell Products (Draft for Comments)"

NMPA: Over 100 Cell and Gene Therapy Products Approved for Clinical Trials

Beijing Issues Document: Explicitly Supports Conducting Clinical Research and Clinical Trials on Cell Therapy in the Field of Plastic Surgery, Reconstruction, and Aesthetics

Gene Editing Therapy Industry Research Report

1.5 Billion! Shenzhen Plans to Establish a Cell and Gene Industry Fund

NMPA Releases New Regulations for Conditional Approval of Innovative Drugs (with Policy Interpretation)

Statement:This article is intended for knowledge sharing. All content is for reference only and does not constitute any advice.